Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.
Kasimir-Bauer S, Roder J, Obermayr E, Mahner S, Vergote I, Loverix L, Braicu E, Sehouli J, Concin N, Kimmig R, Net L, Roder H, Zeillinger R, Aust S, On Behalf Of The Ovcad Ovarian Cancer Diagnosis Initiative. Kasimir-Bauer S, et al. Among authors: vergote i. Cancers (Basel). 2020 Sep 4;12(9):2519. doi: 10.3390/cancers12092519. Cancers (Basel). 2020. PMID: 32899818 Free PMC article.
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Harter P, et al. Among authors: vergote i. Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd. Int J Gynecol Cancer. 2011. PMID: 21270612
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Hofstetter G, et al. Among authors: vergote i. Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18. Br J Cancer. 2011. PMID: 22009029 Free PMC article.
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, Mahner S, Ferschke I, Rom J, Sohn C, Schneeweiss A, Altevogt P. Marmé F, et al. Among authors: vergote i. Int J Cancer. 2012 Aug 15;131(4):E586-91. doi: 10.1002/ijc.27329. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22034009 Free article.
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.
Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R. Pils D, et al. Among authors: vergote i. Cancer Sci. 2012 Jul;103(7):1334-41. doi: 10.1111/j.1349-7006.2012.02306.x. Epub 2012 May 17. Cancer Sci. 2012. PMID: 22497737 Free PMC article.
874 results